Journal
MULTIPLE SCLEROSIS
Volume 15, Issue 6, Pages 728-734Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458509103173
Keywords
clinically definite multiple sclerosis; clinically isolated syndrome; intramuscular interferon beta-1a
Categories
Ask authors/readers for more resources
Approximately 85% of multiple sclerosis (MS) cases begin as clinically isolated syndromes (CIS). Results from the Controlled High-Risk Subjects Avonex (R) Multiple Sclerosis Prevention Study (CHAMPS) demonstrated that, in patients with CIS, treatment with intramuscular (IM) interferon beta-1a (IFN beta-1a) 30 mu g once weekly delayed conversion to clinically definite MS (CDMS) in the total population and in subgroups based on presenting syndromes and baseline magnetic resonance imaging (MRI) characteristics. Changes to clinical and MRI risk classification of presenting symptoms in recent studies prompted reanalysis of CHAMPS data. Presenting syndromes were assessed using a derived algorithm that stratifies patients into mono-or multifocal categories based on functional system scores. The ability of IM IFN beta-1a to delay progression to CDMS in subgroups based on clinical presentation and MRI characteristics was assessed. Reanalysis of CHAMPS patients showed that 30% could be classified by clinical criteria as having multifocal disease at baseline. IM IFN beta-1a initiated at a first demyelinating attack delayed CDMS in monofocal patients (P = 0.0013), patients with or without gadolinium-enhancing lesions (P = 0.0007, P = 0.0405) and patients with at least nine T2 lesions at baseline (P = 0.0044). These data confirm that IM IFN beta-1a delays conversion to CDMS in patients with CIS. Multiple Sclerosis 2009; 15: 728-734. http://msj.sagepub.com
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available